|
Name |
Steffimycin B
|
Molecular Formula | C29H32O13 | |
IUPAC Name* |
(2S,3S,4R)-2,5,7-trihydroxy-4-[(2S,3R,4R,5R,6S)-4-hydroxy-3,5-dimethoxy-6-methyloxan-2-yl]oxy-3,9-dimethoxy-2-methyl-3,4-dihydrotetracene-1,6,11-trione
|
|
SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2[C@@H]([C@](C(=O)C3=CC4=C(C(=C23)O)C(=O)C5=C(C4=O)C=C(C=C5O)OC)(C)O)OC)OC)O)OC
|
|
InChI |
InChI=1S/C29H32O13/c1-10-23(38-4)22(34)25(39-5)28(41-10)42-24-18-14(26(35)29(2,36)27(24)40-6)9-13-17(21(18)33)20(32)16-12(19(13)31)7-11(37-3)8-15(16)30/h7-10,22-25,27-28,30,33-34,36H,1-6H3/t10-,22+,23-,24+,25+,27-,28-,29+/m0/s1
|
|
InChIKey |
VHJWDTPKSIFZBV-IDORXPLKSA-N
|
|
Synonyms |
Steffimycin B; 54526-94-2; NSC 204855
|
|
CAS | 54526-94-2 | |
PubChem CID | 9894712 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 588.6 | ALogp: | 0.8 |
HBD: | 4 | HBA: | 13 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 188.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 42 | QED Weighted: | 0.325 |
Caco-2 Permeability: | -6.217 | MDCK Permeability: | 0.00001480 |
Pgp-inhibitor: | 0.554 | Pgp-substrate: | 0.999 |
Human Intestinal Absorption (HIA): | 0.817 | 20% Bioavailability (F20%): | 0.001 |
30% Bioavailability (F30%): | 0.737 |
Blood-Brain-Barrier Penetration (BBB): | 0.032 | Plasma Protein Binding (PPB): | 84.70% |
Volume Distribution (VD): | 0.967 | Fu: | 25.46% |
CYP1A2-inhibitor: | 0.293 | CYP1A2-substrate: | 0.981 |
CYP2C19-inhibitor: | 0.01 | CYP2C19-substrate: | 0.09 |
CYP2C9-inhibitor: | 0.09 | CYP2C9-substrate: | 0.077 |
CYP2D6-inhibitor: | 0.01 | CYP2D6-substrate: | 0.135 |
CYP3A4-inhibitor: | 0.139 | CYP3A4-substrate: | 0.165 |
Clearance (CL): | 3.725 | Half-life (T1/2): | 0.265 |
hERG Blockers: | 0.005 | Human Hepatotoxicity (H-HT): | 0.269 |
Drug-inuced Liver Injury (DILI): | 0.977 | AMES Toxicity: | 0.438 |
Rat Oral Acute Toxicity: | 0.011 | Maximum Recommended Daily Dose: | 0.075 |
Skin Sensitization: | 0.816 | Carcinogencity: | 0.018 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.063 |
Respiratory Toxicity: | 0.405 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005541 | 0.711 | D01UBX | 0.353 | ||||
ENC005539 | 0.650 | D01XWG | 0.342 | ||||
ENC005540 | 0.640 | D0C9XJ | 0.327 | ||||
ENC001063 | 0.540 | D07VLY | 0.327 | ||||
ENC005542 | 0.476 | D01XDL | 0.311 | ||||
ENC003228 | 0.465 | D0T8EH | 0.308 | ||||
ENC005543 | 0.454 | D0T5XN | 0.304 | ||||
ENC000966 | 0.421 | D0FX2Q | 0.288 | ||||
ENC004539 | 0.415 | D07IPB | 0.287 | ||||
ENC005280 | 0.408 | D06LNW | 0.271 |